The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
AACR 2023 | Overcoming the challenges in utilizing cfDNA in screening for lung cancer
Julie Barta, MD, Thomas Jefferson University, Philadelphia, PA, discusses the challenges in utilizing cell free DNA (cfDNA) in screening for lung cancer and strategies to overcome them. A screening test requires adequate sensitivity to detect early-stage disease. DELFI (DNA evaluation of fragments for early interception) is a technology that uses low-coverage, whole-genome sequencing and machine learning to detect cancer signals in the blood. Initial data from the technical validation of the DELFI test has demonstrated good sensitivity in stage I/II lung cancer and is currently under evaluation in a prospective, observational, blood specimen collection study, CASCADE-LUNG (NCT05306288). The application of cfDNA is additionally being explored for predicting tumor histology or prognosis. This interview took place at the American Association for Cancer Research (AACR) Annual Meeting 2023 in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
